Literature DB >> 29363146

Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant.

Beatrice Casadei1, Cinzia Pellegrini1, Lorenzo Tonialini1, Lisa Argnani1, Pier Luigi Zinzani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29363146     DOI： 10.1002/hon.2492

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  3 in total

1.  Pegylated liposomal doxorubicin for myeloid neoplasms.

Authors:  Cheng Zhang; Han Yao; Pei-Yang Kong; Yao Liu; Lei Gao; Li Gao; Ying-Ying Ma; Jun Liu; Xu Tan; Xi Zhang
Journal:  Anticancer Drugs       Date:  2019-10       Impact factor: 2.248

Review 2.  Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.

Authors:  Stefano Oliva; Agata Puzzovivo; Chiara Gerardi; Eleonora Allocati; Vitaliana De Sanctis; Carla Minoia; Tetiana Skrypets; Attilio Guarini; Guido Gini
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

3.  Lipid-Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo.

Authors:  Guan-Nan Zhang; Pranav Gupta; Ming Wang; Anna Maria Barbuti; Charles R Ashby; Yun-Kai Zhang; Leli Zeng; Qiaobing Xu; Ying-Fang Fan; Zhe-Sheng Chen
Journal:  Cancers (Basel)       Date:  2020-02-21       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.